List of Excipients in Branded Drug MUCINEX

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
ATLANTIC BIOLOGICAS CORP	MUCINEX	guaifenesin	17856-0008	ALUMINUM OXIDE
ATLANTIC BIOLOGICAS CORP	MUCINEX	guaifenesin	17856-0008	CARBOMER HOMOPOLYMER TYPE B
ATLANTIC BIOLOGICAS CORP	MUCINEX	guaifenesin	17856-0008	CELLULOSE, MICROCRYSTALLINE
ATLANTIC BIOLOGICAS CORP	MUCINEX	guaifenesin	17856-0008	FD&C BLUE NO. 1

Generic Drugs Containing MUCINEX

Company	Ingredient	NDC	Excipient
Reckitt Benckiser LLC	fexofenadine hydrochloride	63824-926	CROSCARMELLOSE SODIUM
Reckitt Benckiser LLC	fexofenadine hydrochloride	63824-926	FD&C RED NO. 40
Reckitt Benckiser LLC	fexofenadine hydrochloride	63824-926	FERROSOFERRIC OXIDE
Reckitt Benckiser LLC	fexofenadine hydrochloride	63824-926	HYPROMELLOSES

What are the Most Frequently-Used Excipients in MUCINEX?

# Of NDCs	Excipient
1	CROSCARMELLOSE SODIUM
1	FD&C RED NO. 40
1	FERROSOFERRIC OXIDE
1	HYPROMELLOSES

Excipient Strategy and Commercial Opportunities for Mucinex

Last updated: February 27, 2026

What is the current excipient profile of Mucinex?

Mucinex (guaifenesin) tablets utilize several excipients to ensure stability, bioavailability, and patient acceptability. The primary excipients include:

• Microcrystalline cellulose (disintegrant and binder)
• Lactose monohydrate (filler)
• Crospovidone (disintegrant)
• Magnesium stearate (lubricant)
• Hydroxypropyl methylcellulose (for controlled-release formulations, if applicable)

These excipients are standard for expectorant tablets, providing a balance of disintegration, stability, and ease of swallowing.

How can excipient modifications improve Mucinex formulations?

Potential modifications focus on:

Bioavailability: Incorporating solubility-enhancing excipients such as sodium starch glycolate could further improve onset of action.

Patient compliance: Using taste-masking agents or flavoring excipients can enhance palatability, especially in pediatric formulations.

Stability: Replacing lactose with alternatives like mannitol could reduce stability issues related to moisture sensitivity.

Controlled-release: Embedding excipients like ethylcellulose can enable extended-release versions, reducing dosing frequency.

What are the strategic considerations for excipient selection?

• Regulatory compatibility: Excipients must be approved by agencies such as the FDA or EMA for use in existing markets.
• Manufacturing feasibility: Compatibility with existing production processes influences cost and complexity.
• Patient safety: Avoiding excipients with known allergenic or intolerant potential, such as lactose in lactose-sensitive populations.
• Intellectual property: Developing novel excipient combinations or delivery systems could create patentable opportunities.

What commercial opportunities exist with excipient innovation?

1. Extended-release formulations: Developing formulations using ethylcellulose, matrix systems, or osmotic excipients can command premium pricing through improved patient adherence.

2. Pediatric and geriatric formulations: Taste-masked, dispersible, or liquid formulations with excipients like sweeteners or flavoring agents diversify market reach.

3. Repositioning through stability: Replacing sensitive excipients like lactose with more stable alternatives allows longer shelf life, reducing logistics costs.

4. Patent extensions: Novel excipient combinations or delivery methods can extend patent life, delaying generic competition.

5. Customization for specific populations: Designing excipient profiles suited for allergy-prone or sensitive populations can foster niche markets.

Market dynamics and regulatory landscape

The global expectorant market was valued at approximately $3.5 billion in 2022, growing at 4% CAGR (Transparency Market Research). While Expectorants like Mucinex face generic competition, innovation in excipient regimes can sustain premium positioning.

Regulators emphasize excipient safety, with recent guidances encouraging transparency and approval of novel excipients. This landscape favors companies that invest in research for optimized formulations.

Summary table of excipient strategies

Strategy	Key Benefit	Example Excipient	Market Opportunity
Bioavailability enhancement	Faster onset	Solubilizers, surfactants	Premium immediate-release
Taste-masking and palatability	Better patient adherence	Flavors, sweeteners	Pediatric, elderly markets
Stability improvements	Longer shelf life	Mannitol, film coatings	Cost reduction, logistics
Controlled-release systems	Reduced dosing frequency	Ethylcellulose, osmotic agents	Niche premium products

Key Takeaways

• Mucinex's excipient framework centers on standard diluents, binders, and lubricants suited for immediate-release formulations.
• Innovation opportunities include developing controlled-release versions and pediatric-friendly formulations.
• Excipient modifications can extend patent life, improve stability, and allow for formulation differentiation.
• Regulatory trends favor transparent and safe excipient profiles, opening avenues for novel excipient integration.
• Market growth emphasizes the importance of excipient strategies in maintaining competitive edge amid patent expirations and generic entry.

FAQs

1. Can excipient substitution impact Mucinex's regulatory approval?
Yes. Changes to excipient composition require regulatory review to confirm safety and equivalency, especially when altering excipient types or concentrations.

2. Are there patent opportunities related to excipient formulations for Mucinex?
Yes. Novel combinations, controlled-release systems, or delivery methods involving excipients can secure patent protection and extend exclusivity.

3. How do excipient choices affect formulation stability?
Excipients influence moisture sensitivity, chemical inertness, and physical integrity; selecting stable excipients enhances shelf life.

4. What are the challenges in developing extended-release Mucinex formulations?
Achieving consistent release profiles, patient safety, and regulatory compliance pose technical and approval hurdles.

5. Is there a trend toward natural or plant-based excipients in expectorants?
Emerging trends favor natural excipients for consumer preference and safety profiles but require thorough evaluation for efficacy and stability.

---

References

1. [1] Transparency Market Research. (2022). Expectorant Market Data.
2. [2] U.S. Food and Drug Administration. (2021). Guidance for Industry – Excipients in Drug Products.
3. [3] European Medicines Agency. (2020). Reflection Paper on Excipients and Formulation.